Learn what leading scientists have to say on various topics in pre-clinical pulmonary research with our Webinar and Panel Discussion series!
Coming soon!
Traditional safety pharmacology and toxicology studies often rely on a limited set of endpoints, potentially overlooking subtle physiological changes that could inform compound safety profiles.
This session explored how integrating easyTEL+ implantable telemetry technologies expands the scope of safety assessments.
During our 2025 SOT seminar, William Salvail (IPS Therapeutique Inc) discussed the benefits of implanted digital telemetry to improve the clinical relevance of non-clinical efficacy and toxicity testing, while Dr. Monica Metea (Preclinical Electrophysiology Consulting, LLC) presented advanced methods for streamlining telemetry electrophysiology analytics.
SCIREQ & emka Technologies hosted a webinar on Large Animal Models for Preclinical Studies of Heart Failure, with Dr. Moctezuma-Ramirez from the Texas Heart Institute. Dr. Moctezuma-Ramirez presented the development of their percutaneous myocardial infarction model in pigs, designed to mimic human heart failure with reduced ejection fraction (HFrEF).
During the 2024 Safety Pharmacology Society (SPS) Conference in San Diego, Ken Kearney (Charles River Laboratories) shared the results of a study, evaluating the ability of our jacketed external telemetry system to capture ECG and respiratory data simultaneously, from ECG leads.
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, Dr. Dany Salvail (IPST, QC, Canada) explained how experienced pharmacologists rely on alternate models combined with sophisticated measurement techniques that go well beyond the ICH guidelines to help sponsors truly understand and quantify liabilities associated with their lead compounds early on.
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, Dr. Donald Hodges (CBSET, MA, USA) outlined how proven translational characteristics and historical data are enabling the wider adoption of swine as an alternative to dogs and Non-Human Primates in the context of shortages and rising costs.
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, Dr. Michael Stonerook (AmplifyBio, OH, USA) highlighted the benefits and limitations of the rat model for cardiovascular screening assays.
Finding arrhythmias in rodents can be tedious, thrilling, and controversial. During the 2023 Society of Toxicology (SOT) conference in Nashville, Dr. Alex Carll discussed rodent ECG morphology and physiologic vs. pathologic arrhythmias in mice and rats.
To achieve therapeutic cardiac regeneration, the University of Washington Medicine Heart Regeneration Program has been focusing on remuscularization with genuine cardiomyocytes derived from pluripotent stem-cells.
In our SPS 2022 hosted session, we discussed the Translational Assessment of Pressor Effects of Drugs with Dr.Christine Garnett (FDA), Dr.Todd Wisialowski (Pfizer) and Dr.Brian Roche (Charles River).
Integrating various tools in neuroscience, like video tracking and wireless telemetry, offer a more complete assessment of complex disease models.
In this webinar, you hear about wireless telemetry options in behavioral testing and integration in video tracking experiments. Matt McGuire kindly shares his experiences and insights from his Traumatic Brain Injury (TBI) research at the Dr. Poulsen Lab.
